Alma TEDResource Center
The definitive guide to non-invasive hair restoration with Alma TED. From hormonal hair loss and GLP-1 related thinning to proprietary formulations, training protocols, and advanced applications with exosomes and PRP.
The Hair Restoration Opportunity
Hair loss affects over 80 million Americans, with the global hair restoration market projected to exceed $13 billion by 2028. The convergence of rising GLP-1 medication usage and growing awareness of hormonal hair loss has created unprecedented demand for non-invasive solutions.
30M women and 50M men experience pattern hair loss in the US alone
The global hair restoration market continues to grow at 15.4% CAGR
Nearly half of all adults over 50 will experience noticeable hair loss
Premium pricing with high patient satisfaction and repeat bookings
Why the Timing Is Right
GLP-1 Medication Surge
Over 15 million Americans now use GLP-1 medications like Ozempic and Wegovy. Up to 3% report hair loss as a side effect, creating a massive new patient population seeking solutions.
Post-Pandemic Awareness
Telogen effluvium from COVID-19 stress, combined with increased video conferencing, has made millions more aware of their hair thinning and motivated to seek treatment.
Non-Invasive Preference
Patients increasingly prefer needle-free, painless treatments with no downtime. Alma TED meets this demand perfectly, offering a comfortable 20-30 minute session with zero recovery time.
Hormonal Hair Loss
Androgenetic alopecia is the most common form of hair loss, driven by the hormone dihydrotestosterone (DHT). Understanding the underlying mechanism is essential for positioning Alma TED as a targeted, science-backed solution.
The DHT Mechanism
Testosterone is converted to DHT by the enzyme 5-alpha reductase. In genetically susceptible individuals, DHT binds to receptors in hair follicles, triggering a process called follicular miniaturization. Over successive growth cycles, affected hairs become progressively thinner, shorter, and lighter until the follicle can no longer produce visible hair.
Female Pattern Hair Loss
Affecting approximately 30 million women in the US, female pattern hair loss (FPHL) typically presents as diffuse thinning along the part line and crown. Hormonal shifts during menopause, when estrogen levels decline and relative androgen levels increase, often accelerate the condition. FPHL can begin as early as puberty but is most commonly noticed around menopause.
Male Pattern Hair Loss
Male pattern hair loss (MPHL) affects roughly 50 million men and is characterized by a receding hairline and vertex thinning, classified using the Norwood scale. DHT sensitivity is the primary driver, with genetic predisposition determining which follicles are vulnerable. Without intervention, MPHL is progressive and irreversible.
How Alma TED Addresses Hormonal Hair Loss
The TED+ Hair Care Formula contains Copper Tripeptide-1 (GHK-Cu), which protects follicles from DHT damage and promotes follicular health at the cellular level.
VEGF and aFGF in the formula boost blood vessel formation in the scalp, delivering critical oxygen and nutrients to weakened follicles that DHT has starved of blood supply.
Unlike topical treatments that sit on the surface, Alma TED's ultrasound technology drives active ingredients 4mm deep into the dermis, directly reaching the hair follicle bulb where DHT exerts its effect.
GLP-1 Medications & Hair Loss
The explosive growth of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created a significant new population of patients experiencing hair thinning. This represents both a clinical challenge and a major opportunity for practices offering Alma TED.
The GLP-1 Hair Loss Connection
Clinical trials for semaglutide reported alopecia in approximately 3% of participants. With over 15 million Americans now using GLP-1 medications, this translates to an estimated 450,000+ patients experiencing drug-related hair thinning. The primary mechanism is telogen effluvium triggered by rapid weight loss and nutritional shifts.
Telogen Effluvium Mechanism
Rapid weight loss (more than 20 lbs in a short period) shocks the body, pushing a disproportionate number of hair follicles from the anagen (growth) phase into the telogen (resting/shedding) phase. Nutritional deficiencies in protein, iron, zinc, and biotin from reduced caloric intake compound the problem. Hair shedding typically begins 2-4 months after starting medication.
Compounding Factors
Many GLP-1 patients already have underlying androgenetic alopecia that was previously masked by fuller hair. The telogen effluvium from weight loss unmasks and accelerates this genetic pattern, creating a dual-mechanism hair loss that requires a comprehensive treatment approach.
Why Alma TED Is Ideal for GLP-1 Patients
Non-Invasive Comfort
GLP-1 patients are already managing medication side effects. Alma TED offers a painless, needle-free treatment that doesn't add to their burden. Zero downtime means they can resume normal activities immediately.
Targeted Nutrient Delivery
The TED+ formula delivers growth factors, amino acids, and peptides directly to nutrient-starved follicles, addressing the nutritional deficiency component of GLP-1 hair loss at the follicular level.
Rapid Visible Results
Patients typically notice reduced shedding within 2-4 weeks and visible improvement in hair density by 90 days. This timeline aligns well with the ongoing nature of GLP-1 therapy.
Complementary to Weight Loss Goals
Unlike oral supplements that may interfere with GLP-1 efficacy, Alma TED works topically through ultrasound delivery, making it fully compatible with ongoing weight management programs.
Patient Consultation Talking Points
- •"Hair loss from GLP-1 medications is typically temporary, but treatment can significantly accelerate recovery"
- •"Alma TED delivers nutrients directly where your follicles need them most"
- •"The treatment is completely painless and takes only 20-30 minutes"
- •"We recommend a series of 3 monthly treatments for optimal results"
The Alma TED Device
Alma TED (TransEpidermal Delivery) uses patented acoustic pressure combined with air pressure to drive topical formulations deep into the scalp without needles, pain, or downtime. It is the first and only device of its kind cleared for hair restoration.
Alma TED System
TransEpidermal Delivery Platform
TED+ Hair Care Formula
Proprietary serum containing growth factors, peptides, and amino acids formulated specifically for TED delivery.
How TED Technology Works
Acoustic Pressure Waves
The TED device generates low-frequency ultrasound waves that create transient micropathways in the stratum corneum (outer skin layer) without causing tissue damage. These acoustic waves oscillate at a specific frequency optimized for scalp penetration.
Air Pressure Enhancement
Simultaneously, controlled air pressure pushes the topical solution into the micropathways created by the ultrasound. This dual-mechanism approach achieves penetration depths of up to 4mm, reaching the dermal papilla where hair growth is regulated.
Painless 20-Minute Treatment
The entire treatment takes 20-30 minutes with zero pain. Patients describe a warm, buzzing sensation. No anesthesia is required, no needles are used, and there is absolutely no downtime. Patients can wash their hair the same day.
Targeted Formula Delivery
The TED+ Hair Care Formula is delivered directly to the hair follicle bulb, bypassing the skin barrier that limits topical treatments like minoxidil. This ensures maximum bioavailability of growth factors, peptides, and amino acids.
Key Differentiators vs. Competition
Proprietary Amino Acids & Peptides
The TED+ Hair Care Formula was developed by a world-renowned pharmaceutical research lab. It contains a synergistic blend of growth factors, peptides, amino acids, and hair-anchoring compounds designed to work with the TED delivery system for maximum follicular impact.
Growth Rate
VEGF, aFGF, Copper Tripeptide-1
Stimulates follicular cell proliferation, extends the anagen growth phase, and increases the rate of hair shaft production.
Nutrient & Vessel Network
VEGF, aFGF, Amino Acid Blend
Builds new blood vessels around follicles and delivers the essential amino acids needed for keratin synthesis.
Hair Anchoring
Octapeptide-2, Dimethylsilanediol, Chondrus Crispus
Strengthens the bond between hair and follicle, reduces shedding, and improves the structural integrity of each strand.
Treatment Protocols
Comprehensive protocols for standard Alma TED treatments, advanced combination therapies with PRP and exosomes, TED-assisted numbing for other procedures, and long-term maintenance planning.
Evidence-Based
Clinical Protocols
Standard Alma TED Treatment Protocol
Pre-Treatment Preparation
Patient should arrive with clean, dry hair (no products)
Perform scalp assessment and photograph baseline
Review medical history and confirm no contraindications
Set patient expectations: 3 monthly sessions recommended
Prepare TED+ Hair Care Formula vial (one per treatment)
Treatment Procedure
Power on device and select appropriate treatment settings
Apply TED+ Hair Care Formula to the treatment area
Begin treatment at the frontal hairline, working systematically
Move the handpiece in slow, overlapping passes across the scalp
Ensure complete coverage of all thinning areas (20-30 min total)
Apply remaining serum and allow absorption for 5 minutes
Post-Treatment Instructions
Contraindications
Patient safety is paramount. A thorough screening process must be conducted before every Alma TED treatment. The following contraindications must be reviewed and documented during the consultation.
Absolute Contraindications
Treatment must NOT be performed on patients with any of the following conditions:
Active Scalp Infections
Any bacterial, fungal, or viral infection of the scalp (e.g., folliculitis, tinea capitis, herpes simplex). Treatment must be deferred until the infection is fully resolved.
Open Wounds or Lesions
Cuts, abrasions, burns, or any open wounds on the treatment area. The ultrasound energy could worsen the condition and risk infection.
Pregnancy or Nursing
The safety of TED treatment during pregnancy and lactation has not been established. Defer treatment until after pregnancy and breastfeeding.
Active Malignancy on Scalp
Any known or suspected skin cancer or malignant lesion in the treatment area. Refer to dermatology for evaluation first.
Implanted Electronic Devices
Pacemakers, defibrillators, or other implanted electronic devices near the treatment area. The ultrasound energy may interfere with device function.
Metal Implants in Treatment Area
Metal plates, screws, or implants in the skull or scalp area that could interact with the acoustic energy.
Relative Contraindications
Proceed with caution and physician clearance for patients with:
Autoimmune Conditions
Alopecia areata, lupus, or other autoimmune disorders affecting the scalp. May require coordination with the patient's rheumatologist or dermatologist.
Blood Thinning Medications
Patients on anticoagulants (warfarin, heparin) or antiplatelet drugs. While TED is non-invasive, caution is advised.
Recent Scalp Procedures
Hair transplant surgery, scalp micropigmentation, or other procedures within the past 4-6 weeks. Allow adequate healing time.
Severe Scalp Conditions
Severe psoriasis, eczema, or seborrheic dermatitis in the treatment area. Condition should be stabilized before treatment.
Known Allergies to Ingredients
Review the TED+ formula ingredients with the patient. Perform a patch test if there is any concern about sensitivity.
Ideal Candidates
Additional Uses for TED Technology
The Alma TED platform's TransEpidermal Delivery technology extends far beyond hair restoration. Its ability to drive active ingredients deep into the skin without needles opens up a wide range of aesthetic and clinical applications.
Exosome Delivery
Drive exosomes containing 300+ growth factors, mRNA, and signaling molecules deep into the scalp or skin. Exosomes activate Wnt signaling pathways, promote stem cell differentiation, and accelerate tissue regeneration. TED delivery ensures uniform distribution without the degradation that occurs with injection.
PRP Enhancement
Use TED to deliver Platelet-Rich Plasma deeper and more uniformly than traditional injection methods. The acoustic pressure distributes PRP's PDGF, TGF-beta, and IGF-1 across the entire treatment area rather than concentrated at injection points. Ideal as a needle-free PRP alternative or enhancement.
Numbing Acceleration
Dramatically reduce topical anesthetic onset time from 30-60 minutes to 5-10 minutes. TED drives lidocaine-based numbing agents 3-4mm deep with uniform coverage. Use before PRP injections, fillers, Botox, laser treatments, microneedling, or any procedure requiring topical anesthesia.
Topical Drug Delivery
Enhance the penetration of topical medications including minoxidil, finasteride solutions, and compounded hair loss formulations. TED can increase the bioavailability of these agents by delivering them past the stratum corneum barrier directly to the target tissue.
Skin Rejuvenation
Apply TED technology to deliver hyaluronic acid, vitamin C serums, and anti-aging peptides into facial skin. The non-invasive delivery achieves deeper penetration than manual application, offering a needle-free alternative to mesotherapy for skin hydration and rejuvenation.
Post-Procedure Recovery
Use TED to deliver healing serums and growth factors after laser treatments, chemical peels, or microneedling sessions. The gentle acoustic delivery promotes faster healing without the trauma of additional needle passes on already-treated skin.